307 related articles for article (PubMed ID: 25188482)
1. The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
Orlowski RZ
Oncology (Williston Park); 2011 Nov; 25 Suppl 2(12 0 2):56-64. PubMed ID: 25188482
[TBL] [Abstract][Full Text] [Related]
2. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
3. Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Lonial S; Boise LH
Oncology (Williston Park); 2011 Nov; 25 Suppl 2():25-31. PubMed ID: 25188480
[TBL] [Abstract][Full Text] [Related]
4. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibitors in the treatment of multiple myeloma.
Shah JJ; Orlowski RZ
Leukemia; 2009 Nov; 23(11):1964-79. PubMed ID: 19741722
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors in multiple myeloma: 10 years later.
Moreau P; Richardson PG; Cavo M; Orlowski RZ; San Miguel JF; Palumbo A; Harousseau JL
Blood; 2012 Aug; 120(5):947-59. PubMed ID: 22645181
[TBL] [Abstract][Full Text] [Related]
7. New proteasome inhibitors in myeloma.
Lawasut P; Chauhan D; Laubach J; Hayes C; Fabre C; Maglio M; Mitsiades C; Hideshima T; Anderson KC; Richardson PG
Curr Hematol Malig Rep; 2012 Dec; 7(4):258-66. PubMed ID: 23065395
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
9. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
[TBL] [Abstract][Full Text] [Related]
10. [Proteasome inhibitor].
Yagi H
Nihon Rinsho; 2014 Jun; 72(6):1125-9. PubMed ID: 25016815
[TBL] [Abstract][Full Text] [Related]
11. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Vogl DT; Stadtmauer EA; Tan KS; Heitjan DF; Davis LE; Pontiggia L; Rangwala R; Piao S; Chang YC; Scott EC; Paul TM; Nichols CW; Porter DL; Kaplan J; Mallon G; Bradner JE; Amaravadi RK
Autophagy; 2014 Aug; 10(8):1380-90. PubMed ID: 24991834
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and its role in the management of patients with multiple myeloma.
Orlowski RZ
Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
[TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.
Knopf KB; Duh MS; Lafeuille MH; Gravel J; Lefebvre P; Niculescu L; Ba-Mancini A; Ma E; Shi H; Comenzo RL
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):380-8. PubMed ID: 25023616
[TBL] [Abstract][Full Text] [Related]
14. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
15. Role of carfilzomib in the treatment of multiple myeloma.
Khan RZ; Badros A
Expert Rev Hematol; 2012 Aug; 5(4):361-72. PubMed ID: 22992230
[TBL] [Abstract][Full Text] [Related]
16. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.
Vij R; Siegel DS; Jagannath S; Jakubowiak AJ; Stewart AK; McDonagh K; Bahlis N; Belch A; Kunkel LA; Wear S; Wong AF; Wang M
Br J Haematol; 2012 Sep; 158(6):739-48. PubMed ID: 22845873
[TBL] [Abstract][Full Text] [Related]
17. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
Leleu X; Martin TG; Einsele H; Lyons RM; Durie BGM; Iskander KS; Ailawadhi S
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):9-22. PubMed ID: 30287200
[TBL] [Abstract][Full Text] [Related]
18. Current Phase II investigational proteasome inhibitors for the treatment of multiple myeloma.
Bringhen S; Gay F; Donato F; Troia R; Mina R; Palumbo A
Expert Opin Investig Drugs; 2014 Sep; 23(9):1193-209. PubMed ID: 24905450
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors in the treatment of multiple myeloma.
McBride A; Ryan PY
Expert Rev Anticancer Ther; 2013 Mar; 13(3):339-58. PubMed ID: 23477520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]